ORIONS Money Stocks

[BioSpecialist]

BXRX =MC $86 m a great buying opp after the drop


https://www.rttnews.com/3071353/baudax-bio-s-bxrx-non-opioid-pain-drug-makes-it-to-the-finish-line.aspx

ANJESO that will be administered as a once-a-day intravenous (IV) bolus push is the only available 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) and offers once-daily dosing.

Baudax expects ANJESO to be available in the U.S. in late April or early May 2020.

Esther Hong, an analyst at Janney Montgomery, estimates peak sales of the drug in the U.S. to reach about $355 million.